Colorectal cancer: a drug in test that destroys the tumor without surgery or chemo


Colorectal cancer: a drug in test that destroys the tumor without surgery or chemo
Written by madishthestylebar

among all rectal cancerthem adenocarcinomas are the most frequent. To cure them, oncologists usually offer surgery to remove the cancerous area, followed by a chemotherapy. But, for a long time, interleukin 2 and interferon have been the two most…” data-image=” b/4/3b4d8dc18b_132423_immunotherapy-syringe.jpg” data-url=”” data-more=”Read more”>immunotherapy could replace this protocol burdensome for patients. In effect, a small clinical trial made at Memorial Sloane Kettering Cancer Center in New York gave impressive results: 100% of patients were in remissionwithout the need for surgery or chemotherapy, after treatment with a Structure of an antibody
An antibody is a protein complex. While each organism with an immune system codes for billions of different antibodies, they all have the same overall characteristics. These are…” data-image=”” data-url=”https: //” data-more=”Read more”>antibody therapy, dostarlimab.

100% remission

Tested on a small Historically, a Roman legion had ten cohorts numbered from I to X. © Peter Bernik, Shutterstock
Cohort study
A study of…” data-image=”” data-url=”https://news” data-more=”Read more”>cohort of twelve patients, suffering from phase II or III rectal adenocarcinoma, dostarlimab made it possible to eradicate purely and simply the tumor after one injection every three weeks for six months. In 100% of patients, the tumor was undetectable at to scanMRI,endoscopy and in biopsies rectal. They did not need surgery or chemotherapy to complete the action of dostarlimab. No patient had a relapse during the follow-up period, which lasted from 6 to 25 months. Dostarlimab did not cause serious side effects in most patients, only rashes, fatigue, nausea, and nausea. These histamines bind to sensory receptors on nerve fibers in the skin responsible for itching sensations.” data-url=”” data-more=”Read the definition”>pruritus. Only one person developed a non-life-threatening thyroid problem.

Dostarlimab also offers hope for people with syndrome of Lynch – eight among the twelve participants in theclinical test. This hereditary disease drastically increases the risk of developing cancer colorectal cancer throughout life, and is associated with poorer outcomes after surgery or cancer chemotherapy. L’immunotherapy could be a promising tool to treat patients affected by Lynch syndrome.

Lasting results?

This approach only works on cancers of the Rectum function
The rectum is the terminal part of the colon, which leads to the anus. The anal sphincter stores faeces in the rectal ampulla before dejection.
The rectum is involved in…” data-image=”” data-url=”” data-more=”Read more”>rectum so-called deficient mismatch system of DNA structure
DNA is a very long molecule, made up of a succession of nucleotides attached to each other by phosphodiester bonds. There are four…” data-image=”” data-url=”https:/ /” data-more=”Read more”>DNA, which represent between 10 to 15% of rectal adenocarcinomas diagnosed each year. Dostarlimab is an antibody that prevents recognition of the PD-1 receptor, located on the lymphocytes T, with sound ligand PDL-1, located on cancer cells. The interaction of the receptor with its ligand paralyzes the immune responseinstead of destroying the abnormal cell, the T lymphocyte spares it. By mechanically blocking this interaction, dostarlimab allows T cells to destroy the abnormal cell.

Impressive results that will need to be replicated in future independent clinical trials involving more participants. The question of the sustainability results will also be crucial; if the participants have been in remission for several months, there is nothing to say to date that they will still be in several years.

Interested in what you just read?


#Colorectal #cancer #drug #test #destroys #tumor #surgery #chemo


About the author


Leave a Comment